Clinical Policy: Rozanolixizumab-noli (Rystiggo)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.648 alerts
Get alerted when Policy CP.PHAR.648 changes without checking for updates manually.
Monitor payer policy activity
Prior authorization and medical-necessity coverage for Rystiggo in adults with anti-AChR- or anti-MuSK-positive generalized myasthenia gravis across commercial, HIM/ICHRA, and Medicaid lines of business.
The 2024 annual revision added the 420 mg/3 mL, 560 mg/4 mL, and 840 mg/6 mL formulations, updated quantity limits to one vial, and added Bkemv, Epysqli, and Zilbrysq to therapies that should not be prescribed concurrently with Rystiggo.
The 2025 annual revision clarified that required immunosuppressive therapy for generalized myasthenia gravis must be non-steroidal and extended Medicaid and HIM approval durations from 6 to 12 months.
The 2026 annual revision added Imaavy and Uplizna to the therapies that should not be prescribed concurrently with Rystiggo and added the ICHRA line of business.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.